Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allergan Tazoral PACT Program Will Register, Certify Physicians/Pharmacies

This article was originally published in The Pink Sheet Daily

Executive Summary

Mandatory pregnancy prevention registry will issue ID numbers upon physician/pharmacist certification and patient qualification. Tazarotene efficacy shown in moderate to severe psoriasis, but not in very severe disease, FDA says. Agency expresses concern about off-label use in acne.

You may also be interested in...



Accutane Legislation Planned; Rep. Stupak Wants Mandatory Registries

The registry would require participation of all patients, prescribers, and dispensers of isotretinoin. Stupak calls into question the ability of Roche and FDA to manage such a registry.

FDA Antihypertensive Draft Class Labeling To Be Reviewed By Cardio-Renal Committee

FDA’s proposal for relabeling of antihypertensive agents is based on prior recommendations by the committee that information on cardiovascular outcomes related to blood pressure lowering be included as class labeling.

Bristol Sprycel For Gleevec-Resistant Leukemia To Get Committee Review At June ASCO Meeting

FDA’s Oncologic Drugs Advisory Committee will meet in Atlanta to review Bristol’s multi-targeted kinase inhibitor dasatinib for two leukemia indications.

Topics

UsernamePublicRestriction

Register

PS143249

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel